NEO

19.56

6.54% 1.20

Pre-mercato: 19.80 0.24 +1.23%

Neogenomics Inc (NEO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NEO Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$18.36

Aprire:

$18.47

Volume 24 ore:

2.95M

Relative Volume:

1.15

Capitalizzazione di mercato:

$2.51B

Reddito:

$745.97M

Utile/perdita netta:

$-99.21M

Rapporto P/E:

-25.31

EPS:

-0.7729

Flusso di cassa netto:

$-5.09M

1 W Prestazione:

-1.66%

1M Prestazione:

+19.20%

6M Prestazione:

+148.85%

1 anno Prestazione:

+148.54%

Intervallo 1D:

$18.40

$19.73

Intervallo di 1 settimana:

$18.27

$20.05

Portata 52W:

$7.065

$20.05

Neogenomics Inc Stock (NEO) Company Profile

Nome

Neogenomics Inc

Settore

Healthcare (1068)

Industria

Diagnostics & Research (49)

Telefono

(239) 768-0600

Indirizzo

9490 NEOGENOMICS WAY, FORT MYERS, FL

Dipendente

2,500

Cinguettio

@NeoGenomics

Prossima data di guadagno

2026-10-27

Ultimi documenti SEC

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, NTRA, A, IQV

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NEO Neogenomics Inc	19.56	2.51B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	678.39	250.83B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	223.77	157.31B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	408.79	58.92B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	172.84	48.73B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	275.02	45.27B	16.63B	1.39B	2.12B	8.0674

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-30	Downgrade	BTIG Research	Buy → Neutral
2025-07-29	Downgrade	William Blair	Outperform → Mkt Perform
2025-05-15	Iniziato	Guggenheim	Neutral
2025-04-30	Downgrade	Leerink Partners	Outperform → Market Perform
2025-01-13	Downgrade	The Benchmark Company	Buy → Hold
2024-12-10	Iniziato	Jefferies	Buy
2024-05-01	Ripresa	Craig Hallum	Buy
2023-12-29	Reiterato	BTIG Research	Buy
2023-08-21	Aggiornamento	Stephens	Equal-Weight → Overweight
2023-05-16	Downgrade	Raymond James	Outperform → Mkt Perform
2023-05-09	Aggiornamento	BTIG Research	Neutral → Buy
2023-02-24	Aggiornamento	The Benchmark Company	Hold → Buy
2023-02-01	Aggiornamento	Needham	Hold → Buy
2022-08-26	Downgrade	The Benchmark Company	Buy → Hold
2022-08-22	Downgrade	Needham	Buy → Hold
2022-06-03	Iniziato	Piper Sandler	Overweight
2022-03-29	Downgrade	BofA Securities	Buy → Neutral
2022-03-29	Downgrade	Stephens	Overweight → Equal-Weight
2022-01-18	Ripresa	Stephens	Overweight
2021-12-16	Iniziato	Cowen	Outperform
2021-11-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-03	Iniziato	Goldman	Buy
2021-02-25	Ripresa	Needham	Buy
2021-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
2021-01-28	Iniziato	Truist	Buy
2020-12-11	Ripresa	BTIG Research	Buy
2020-10-28	Reiterato	Needham	Buy
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-08-28	Iniziato	Guggenheim	Buy
2020-07-29	Reiterato	Needham	Buy
2020-06-25	Iniziato	BofA/Merrill	Buy
2020-04-21	Ripresa	Stephens	Overweight
2020-03-02	Ripresa	Craig Hallum	Buy
2020-02-28	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Reiterato	Needham	Buy
2019-05-01	Reiterato	Needham	Buy
2019-03-29	Reiterato	Needham	Buy
2019-01-03	Iniziato	Needham	Buy
2018-10-24	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Iniziato	Leerink Partners	Outperform
2018-05-02	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Downgrade	BTIG Research	Buy → Neutral
2017-08-24	Iniziato	Gabelli & Co	Buy
2016-12-15	Iniziato	Cantor Fitzgerald	Overweight

Mostra tutto

Neogenomics Inc Borsa (NEO) Ultime notizie

Sep 24, 2026

Precision Oncology Expansion Could Be A Game Changer For NeoGenomics Stock - simplywall.st

Sep 22, 2026

Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily

Sep 22, 2026